Epofolate | BMS753493 |CAS#958646-17-8

MedKoo Cat#: 201275 | Name: Epofolate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Epofolate is folate receptor-targeting antimitotic agent with potential antineoplastic activity. Folate receptor-targeted epothilone BMS753493 contains an epothilone moiety linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the antimitotic epothilone component into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the epothilone moiety induces microtubule polymerization and stabilizes microtubules against depolymerization, resulting in the inhibition of mitosis and cellular proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Chemical Structure

Epofolate

CAS#958646-17-8

Theoretical Analysis

MedKoo Cat#: 201275

Name: Epofolate

CAS#: 958646-17-8

Chemical Formula: C67H92N16O22S3

Exact Mass: 1568.5734

Molecular Weight: 1569.74

Elemental Analysis: C, 51.27; H, 5.91; N, 14.28; O, 22.42; S, 6.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Code name: BMS753493; BMS-753493; BMS 753493.

IUPAC/Chemical Name

(2R,5S,8S,11S,16S)-16-(4-(((2-amino-4-oxo-4,8-dihydropteridin-6-yl)methyl)amino)benzamido)-5,11-bis(carboxymethyl)-2-(((2-(((2-((1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-5,9-dioxo-4-oxa-17-azabicyclo[14.1.0]heptadecan-17-yl)ethoxy)carbonyl)oxy)ethyl)disulfanyl)methyl)-8-(3-guanidinopropyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazaheptadecanedioic acid

InChi Key

TURJYGRXEJIBGT-OCOMGVANSA-N

InChi Code

InChI=1S/C67H92N16O22S3/c1-32-9-7-11-45-46(26-47(33(2)23-38-30-106-35(4)74-38)105-52(90)27-48(84)67(5,6)55(92)34(3)54(32)91)83(45)19-20-103-66(102)104-21-22-107-108-31-44(63(100)101)80-60(96)43(25-51(88)89)79-58(94)40(10-8-18-71-64(68)69)77-59(95)42(24-50(86)87)76-49(85)17-16-41(62(98)99)78-57(93)36-12-14-37(15-13-36)72-28-39-29-73-56-53(75-39)61(97)82-65(70)81-56/h12-15,23,29-30,32,34,40-48,54,72,84,91H,7-11,16-22,24-28,31H2,1-6H3,(H,76,85)(H,77,95)(H,78,93)(H,79,94)(H,80,96)(H,86,87)(H,88,89)(H,98,99)(H,100,101)(H4,68,69,71)(H3,70,73,81,82,97)/b33-23+/t32-,34+,40-,41-,42-,43-,44-,45+,46-,47-,48-,54-,83?/m0/s1

SMILES Code

O=C(O)[C@H](CSSCCOC(OCCN([C@@]1([H])C[C@@H](/C(C)=C/C2=CSC(C)=N2)OC(C[C@H](O)C3(C)C)=O)[C@]1([H])CCC[C@H](C)[C@H](O)[C@@H](C)C3=O)=O)NC([C@H](CC(O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(O)=O)NC(CC[C@H](NC(C4=CC=C(NCC5=CNC6=NC(N)=NC(C6=N5)=O)C=C4)=O)C(O)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Epofolate is a synthetic conjugate of Epothilone and folic acid. Epofolate is currently investigated by Bristol-Myers Squibb as an anticancer drug candidate. As of 2010, this agent is in Phase 1/2 clinical study. The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493) in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate (BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian, renal or breast cancer (in Phase 2 portion). Assigned Interventions: Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses (source: http://clinicaltrials.gov/ct2/show/NCT00546247). BMS-753493 is a molecule born from a collaboration between scientists at Endocyte Inc. and Bristol Myers Squibb (BMS). It represents a FA conjugate that was constructed with a semi-synthetic analog of Epothilone A. BMS-753493 is currently being evaluated for safety and efficacy in Phase 2 clinical trials sponsored by BMS. BMS-753493 is a molecule born from a collaboration between scientists at Endocyte Inc. and Bristol Myers Squibb (BMS). It represents a FA conjugate that was constructed with a semi-synthetic analog of Epothilone A. BMS-753493 is currently being evaluated for safety and efficacy in Phase 2 clinical trials sponsored by BMS.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,569.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Vlahov IR, Vite GD, Kleindl PJ, Wang Y, Santhapuram HK, You F, Howard SJ, Kim SH, Lee FF, Leamon CP. Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4578-81. Epub 2010 Jun 8. PubMed PMID: 20594844.